Results of premarketing and postmarketing trials have raised doubts about the cardiovascular safety of the non-steroidal anti-inflammatory drug (NSAID) rofecoxib, especially at doses greater than 25 mg. Between Jan 1, 1999, and June 30, 2001, we did a retrospective cohort study of individuals on the expanded Tennessee Medicaid programme (TennCare), in which we assessed occurrence of serious coronary heart disease (CHD) in non-users (n=202916) and in users of rofecoxib and other NSAIDs (rofecoxib n=24 132, other n=151 728). Participants were aged 50-84 years, lived in the community, and had no life-threatening non-cardiovascular illness. Users of high-dose rofecoxib were 1.70 (95% CI 0.98-2.95, p=0.058) times more likely than non-users to have CHD; among new users this rate increased to 1.93 (1.09-3.42, p=0.024). By contrast, there was no evidence of raised risk of CHD among users of rofecoxib at doses of 25 mg or less or among users of other NSAIDs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(02)11131-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
National assessment on the frequency of pain medication prescribed for intrauterine device insertion procedures within the Veterans Affairs Health Care System.
PLoS One
January 2025
US Department of Veterans Affairs, Palo Alto Healthcare System, National Center for Collaborative Healthcare Innovation, Palo Alto, California, United States of America.
Background: The intrauterine device (IUD) is a highly effective form of long-acting reversible contraception, widely recognized for its convenience and efficacy. Despite its benefits, many patients report moderate to severe pain during and after their IUD insertion procedure. Furthermore, reports suggest significant variability in pain control medications, including no adequate pain medication.
View Article and Find Full Text PDFMachine Learning-Driven Prediction, Preparation, and Evaluation of Functional Nanomedicines Via Drug-Drug Self-Assembly.
Adv Sci (Weinh)
January 2025
Yunnan Key Laboratory of Stem Cell and Regenerative Medicine, Kunming Medical University, Kunming, 650500, China.
Small molecules as nanomedicine carriers offer advantages in drug loading and preparation. Selecting effective small molecules for stable nanomedicines is challenging. This study used artificial intelligence (AI) to screen drug combinations for self-assembling nanomedicines, employing physiochemical parameters to predict formation via machine learning.
View Article and Find Full Text PDFComparison of the Inhibitory Effects of Flunixin Meglumine and Meloxicam on the Smooth Muscles Motility of the Gastrointestinal Tract of Cattle.
Vet Med Sci
January 2025
Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Türkiye.
This study aimed to compare the inhibitory effect of flunixin meglumine and meloxicam on the smooth muscles of the gastrointestinal tract in male cattle. Tissue samples, including the abomasum, ileum, proximal loop and centripetal gyri of the ascending colon, were collected from routinely slaughtered male cattle. These samples were sectioned into strips and mounted in an isolated tissue bath system.
View Article and Find Full Text PDFSystematic review and meta-analysis of pain management after tonsillectomy.
Sci Rep
January 2025
Department of Otorhinolaryngology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.
Tonsillectomy is one of the most common operations. Tonsillectomy is also one of the most painful surgical procedures. However, there is still no satisfactory standard for postoperative pain management.
View Article and Find Full Text PDFThe effect of meloxicam at the time of treatment of hoof-horn lameness in pasture-grazing dairy cattle on time to lameness soundness, pregnancy risk and time to conception; a randomized control trial.
J Dairy Sci
January 2025
Boehringer-Ingelheim Animal Health, Level 2, 3 Te Kehu Way, Mount Wellington, Auckland, New Zealand.
The aims of this study were to assess the effect of meloxicam at the time of lameness treatment for hoof-horn (HH) lesions in dairy cattle on 1) time to lameness soundness post trimming and block application and 2) reproductive success Five seasonal-calving pasture-based dairy farms located in the Waikato region of New Zealand were enrolled into a randomized clinical interventional trial. Farmers were tasked with identifying lame animals over a period of approximately -4 to 6 weeks relative to the herd start of mating (HSM), with lameness subsequently confirmed with lameness score (LS) by trained technicians (0-3 scale, where ≥2 are considered lame). Animals with a LS ≥2 were examined by a veterinarian who then enrolled animals if they presented lame with HH (white-line or sole) lesions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!